Galectin Therapeutics
GALT
98 hedge funds and large institutions have $48.1M invested in Galectin Therapeutics in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 10 closing their positions.
1,421% more call options, than puts
Call options by funds: $6.14M | Put options by funds: $404K
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
17% more funds holding
Funds holding: 84 → 98 (+14)
10% more capital invested
Capital invested by funds: $43.9M → $48.1M (+$4.25M)
1.94% more ownership
Funds ownership: 16.1% → 18.05% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.5M |
| 2 |
Jane Street
New York
|
+$972K |
| 3 |
6CM
683 Capital Management
New York
|
+$856K |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$749K |
| 5 |
Millennium Management
New York
|
+$659K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$841K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$706K |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$615K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$522K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$375K |
GALT Hedge Fund Activity: Q4 2025 in Review
98 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2025, worth a combined $48.1M — up 9.7% from $43.9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new GALT positions and 10 closed out — a net gain of 15 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $1.5M. The largest seller was Susquehanna International Group, cutting an estimated $841K.
- 98 institutional investors held Galectin Therapeutics (GALT) as of Q4 2025, up from 84 in Q3 2025.
- Funds reported $48.1M of Galectin Therapeutics stock for Q4 2025, up 9.7% quarter-over-quarter.
- 25 funds opened new Galectin Therapeutics positions in Q4 2025 and 10 closed out, a net change of +15 holders.
- The largest Galectin Therapeutics buyer in Q4 2025 was Goldman Sachs, an estimated $1.5M added.
- The largest Galectin Therapeutics seller in Q4 2025 was Susquehanna International Group, an estimated $841K sold.
Based on aggregated 13F filings for Q4 2025.